Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-03-13FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for the calcipotriene and betamethone dipropionate product submitted by Prasco Laboratories.
-
FDA approval · 2014-03-04FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab from Janssen Biotech, Inc., leading to changes in its labeling/approved use.
-
CLINICAL_TRIALS trial_result · 2014-03-04Clinical Trial Update: A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies [Phase 3]
The entry reports a completed Phase 3 study evaluating efalizumab for adults with plaque psoriasis, including those on concomitant antipsori…
-
FDA label_change · 2014-02-26FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
FDA approves a supplemental application for Taclonex (calcipotriol and betamethone dipropionate) from LEO Pharma Inc., updating the product …
-
FDA approval · 2013-12-13FDA Approved: TAZORAC — Supplemental Application (Almirall, LLC)
The FDA approved a supplemental application for TAZORAC (tazarotene) filed by Almirall, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-11-07FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental application for TACLONEX, the fixed-dose combination of calcipotriene and betamethasone dipropionate, submit…
-
CLINICAL_TRIALS trial_result · 2013-11-07Clinical Trial Update: Moderate to Severe Plaque Psoriasis With Scalp Involvement [Phase 4]
Phase 4 clinical trial update from Amgen evaluating moderate-to-severe plaque psoriasis with scalp involvement; results posted on November 7…
-
CLINICAL_TRIALS trial_result · 2013-10-22Clinical Trial Update: Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial of Onercept for moderate to severe plaque psoriasis, including treatment and re-treatment, has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-09-05Clinical Trial Update: A Phase 2 Clinical Study of KHK4827 [Phase 2]
Update on a Phase 2 study of KHK4827 for moderate to severe plaque psoriasis; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2013-08-19Clinical Trial Update: Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients [Phase 1]
This is a completed Phase 1 trial evaluating the pharmacokinetics and safety of the investigational compound M518101 in patients with plaque…
-
FDA approval · 2013-06-28FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for Taclonex (calcipotriene and betamethone dipropionate) from LEO Pharma Inc., resulting in updated…
-
CLINICAL_TRIALS trial_result · 2013-06-13Clinical Trial Update: n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis [Phase 4]
Phase 4 clinical trial evaluating a diet rich in omega-3 polyunsaturated fatty acids for plaque psoriasis (including participants with obesi…
-
CLINICAL_TRIALS trial_result · 2013-05-07Clinical Trial Update: Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis [NA]
Open-label study evaluating maintenance dosing of etanercept in obese patients with moderate to severe plaque psoriasis; results were posted…
-
FDA approval · 2013-04-29FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab from Janssen Biotech, expanding its labeling and indications.
-
FDA approval · 2013-04-25FDA Approved: CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE — Supplemental Application (Prasco Laboratories)
FDA approves a supplemental application for CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE submitted by Prasco Laboratories.
-
CLINICAL_TRIALS research · 2013-04-25Clinical Trial Update: A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118 [Phase 1, Phase 2]
A Phase 1/2 dose-ranging, evaluator-blinded trial evaluating the safety of topical IDP-118 in plaque psoriasis; status is UNKNOWN.
-
FDA approval · 2013-04-24FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approved a supplemental application for Humira (adalimumab) submitted by Cordavis Limited.
-
FDA approval · 2013-04-11FDA Approved: DESOXIMETASONE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's desoximetasone topical product under an Original Application for the treatment of inflammatory and pruriti…
-
CLINICAL_TRIALS trial_result · 2013-03-05Clinical Trial Update: Cell Responses to IFN-gamma [EARLY_Phase 1]
Early-phase clinical trial studying cell responses to interferon-gamma in plaque psoriasis; the study status is terminated.
-
CLINICAL_TRIALS trial_result · 2013-02-28Clinical Trial Update: Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
This clinical trial update assesses the long-term effectiveness and safety of alefacept (Amevive) in adults with moderate to severe chronic …
-
CLINICAL_TRIALS trial_result · 2013-02-15Clinical Trial Update: Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy [Phase 4]
Phase 4 clinical trial update on alefacept in chronic plaque psoriasis patients who failed anti-TNF therapy; the study was terminated and re…
-
CLINICAL_TRIALS trial_result · 2013-02-08Clinical Trial Update: A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial comparing two dosing regimens of ABT-874 (briakinumab) to placebo in adults with moderate to severe chronic plaque psoriasis h…
-
FDA approval · 2013-02-07FDA Approved: SANDIMMUNE — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SANDIMMUNE (cyclosporine) from Novartis, indicating updated labeling or expanded use via a suppl…
-
CLINICAL_TRIALS research · 2013-01-30Clinical Trial Update: Open Label Continuation Study in Moderate to Severe Psoriasis [Phase 3]
This clinical trial update notes that the open-label continuation Phase 3 study in moderate to severe plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-29Clinical Trial Update: A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 study comparing ABT-874 with methotrexate in subjects with moderate to severe plaque psoriasis has completed.